Plain-English translation of NCT05316129 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a brand-new treatment called FSHCER T cells for people with ovarian cancer that has come back after chemotherapy. The researchers take your own immune cells, genetically engineer them in the lab to recognize cancer cells, and then infuse them back into your body to fight the cancer. This is a Phase 1 trial, which means the main goal is to make sure this treatment is safe.
Many women with ovarian cancer that returns after chemotherapy have very few treatment options left, and the cancer often stops responding to standard therapies. This trial is exploring whether engineering your own immune cells to specifically target cancer could offer a new hope for patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You will have your own T cells (immune cells) collected from your blood in the lab. These cells will be genetically engineered to recognize cancer cells, grown in larger numbers, and then infused back into your body either through your veins or directly into your abdomen. The trial will carefully monitor you for side effects and how well the treatment works, with follow-up visits and tests to track your response over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States